Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are emerging public health threats. NAFLD is a common chronic liver disease, with estimates of incidence around 25% worldwide. NASH represents the more severe end of the NAFLD spectrum and there are currently no approved therapeutics to treat NASH. Researchers urgently require better availability of preclinical models to study these global health problems.
Join Dr. Janell Richardson, as she discusses the new off the shelf Diet Induced NASH B6 from Taconic Biosciences and recently released phenotypic characterization data for this model, including some comparison to C57BL/6J mice on a similar diet.
Key takeaways from this webinar include:
Dr. Janell Richardson is a field applications scientist at Taconic Biosciences. She received her Ph.D. in Pharmacology from Georgetown University in 2012. She completed her postdoctoral training at Western University of Health and Sciences in the department of pharmaceutical sciences. Following her postdoctoral training, she entered the commercial sector in 2015 as a scientist at Circuit Therapeutics. From 2016 to 2018, she was a scientific lead for the drug discovery metabolic syndrome portfolio. In November 2018, she joined Taconic providing scientific support to the commercial portfolio.
© 2021 Taconic Biosciences, Inc. All rights reserved.